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Introduction: Iron is a key element in the transport and utilization of oxygen
and a variety of metabolic pathways. Iron deficiency is a major cause of
anemia and can be associated with fatigue, impaired physical function and
reduced quality of life. Administration of oral or intravenous (i.v.) iron is
the recommended treatment for iron-deficiency anemia (IDA) in different
therapeutic areas.
Areas covered: This article provides an overview of studies that evaluated i.v.
iron sucrose for anemia and iron status management, either alone or in com-
bination with erythropoiesis-stimulating agents, across various diseases
and conditions.
Expert opinion: Iron sucrose is an established, effective and well-tolerated
treatment of IDA in patients with acute or chronic conditions such as chronic
kidney disease, inflammatory bowel disease, pregnancy (second and third tri-
mester), postpartum period, heavy menstrual bleeding and cancer who need
rapid iron supply and in whom oral iron preparations are ineffective or not
tolerated. Available data on patient blood management warrant further
studies on preoperative iron treatment. First experience with iron sucrose
follow-on products raises questions about their therapeutic equivalence
without comparative clinical data in newly diagnosed patients or patients
on existing chronic treatment.
Keywords: anemia, efficacy, follow-on products, generics, iron deficiency, iron sucrose,
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1. Introduction to iron deficiency and anemia
Iron deficiency (ID) and iron-deficiency anemia (IDA) are leading causes of disabil-
ity [1] and common complications in a wide range of conditions such as chronic kid-
ney disease (CKD), inflammatory bowel disease and other gastrointestinal disorders,
pregnancy/postpartum, heavy menstrual bleeding, cancer and chronic heart failure
(CHF) [2-8]. Main pathological contributors to ID and IDA are chronic bleeding,
malabsorption and inflammation [9,10]. In addition to the impact on patients, ane-
mia comprises an economic burden in terms of increased average annual health
care cost per patient even after adjustment for disease severity [11]. Since the involve-
ment of iron in hemoglobin (Hb)-dependent oxygen transport is only one key role
of iron apart from its involvement in essential metabolic pathways [12,13], ID, even
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without anemia, can be associated with fatigue, impaired
physical function and reduced quality of life [14,15].
Accordingly, treatment of ID/IDA is an important aspect
in reducing morbidity and improving quality of life. Iron
administration is recommended by treatment guidelines in
different therapeutic areas [4,6,16-21]. In general, the effective-
ness of parenteral (intravenous [i.v.]) iron and the time to
response are superior or at least equivalent to that with oral
iron. Since i.v. iron is directly taken up by the reticuloendo-
thelial system (RES) [22], it can overcome the low intestinal
absorption [23] as well as most of the gastrointestinal side
effects that limit the use of oral iron. Apart from the better
tolerability of parenteral compared to oral iron, the decision
for i.v. or oral iron as first-line therapy depends on the
type of ID (absolute vs functional), the urgency to achieve a
treatment effect, tolerability and costs.
ID can be characterized as absolute ID (i.e., depleted iron
stores) or functional ID (FID, i.e., impaired or suboptimal
availability of iron despite normal or even elevated iron
stores). Absolute ID may be a consequence of chronic blood
loss (e.g., due to heavy menstrual bleeding), increased iron
needs (e.g., in pregnancy), low dietary iron or impaired
absorption. In patients with absolute ID, a trial of oral
iron should be considered first [20,24] if resolution of ID is
not time critical. Slow response to oral iron (due to low
absorption) [23] is particularly limiting in preoperative ane-
mia treatment (also known as patient blood management,
PBM) [17,25].
The FID is mainly associated with chronic diseases (inflam-
mation-driven iron sequestration leading to anemia of chronic
disease [ACD] [10,26]) and/or rapidly increased iron consump-
tion (e.g., due to treatment with erythropoiesis-stimulating
agents, ESAs [10,27]).
In patients with FID due to inflammation, the
ferroportin-mediated release of iron from enterocytes and
macrophages can be reduced by hepcidin, the main regulator
of iron homeostasis, which in turn is upregulated by proin-
flammatory cytokines [2,10,28]. Consequently, the already
low intestinal absorption of orally ingested iron in healthy
individuals is further reduced by > 50% in patients with
chronic inflammatory conditions [28], which may lead to
ACD if left untreated. Conversely, i.v. iron complexes that
are directly taken up by macrophages can overcome the
reduced (and not fully blocked) iron release in patients
with chronic disease [2]. Notably, iron homeostasis can also
be influenced by hypoxia and cellular ID via hepcidin-
independent factors (e.g., hypoxia-inducible factors [HIFs],
especially HIF-2) [26,29]. Therefore, hepcidin levels should
not serve as surrogate marker for iron status or response to
anemia treatment.
In patients with FID due to erythropoietin therapy, oral
iron treatment may be sufficient in individuals with normal
iron absorption. However, in patients with impaired
iron absorption (e.g., patients with cancer or inflammatory
disorders), i.v. iron therapy is required.
2. Market overview of parenteral iron
preparations
Currently available iron carbohydrate preparations for i.v.
iron treatment are based on six compounds: iron sucrose
(IS), ferric gluconate, ferric carboxymaltose, iron dextran
(high- and low-molecular-weight dextran), iron isomaltoside
and ferumoxytol (Table 1) [30]. The use of IS continuously
increased from 2003 to 2009, and in 2005, IS became the
leading i.v. iron compound surpassing ferric gluconate [31].
In the first quarter of 2009, quarterly sales expressed in
100 mg iron dose equivalents were approximately 4.7 million
(IS), 2.6 million (ferric gluconate) and 0.6 million (iron
dextran). The other compounds were not included in this
analysis since they entered the market at a later stage.
Notably, high-molecular-weight iron dextran has been
associated with significantly higher annual reports of total
and life-threatening adverse drug events than other i.v. iron
compounds [32] and is not approved in Europe.
In the recent years, follow-on products of IS (so-called IS
similars) have entered the market. These products have been
approved as generics; however, there is growing clinical [33-36]
and nonclinical [34,37] evidence questioning the interchange-
ability of originator IS with such IS similars [38,39]. Since
generic follow-on products can be marketed under the same
international nonproprietary name as the originator products,
no reliable data about the market share of these follow-on
products are available.
Box 1. Drug summary.
Drug name Iron sucrose, Venofer
Phase Post-marketing, launched
Indication Where there is a clinical need for a rapid iron supply.
In patients who cannot tolerate oral iron therapy or who are noncompliant.
In active inflammatory bowel disease where oral iron preparations are ineffective
Pharmacology description Anti-anemic iron preparation for parenteral use
Route of administration Intravenous
Chemical formula [Na2Fe5O8(OH) * 3(H2O)]n * m(C12H22O11)
Pivotal trial(s) The iron sucrose complex was developed before formal clinical development plans became as usual
as today. Therefore, published, representative studies using Venofer in a variety of patient
populations were selected for inclusion in this review.
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3. Characteristics of the product and its
administration
The medicinal product Venofer (Vifor Pharma Ltd., active
substance: iron as iron(III)-hydroxide sucrose complex, aver-
age molecular weight 45,700 Da) is a dark brown, colloidal
solution that contains 20 mg iron per ml (Box 1). It is avail-
able in ampoules or vials with 5 ml solution (100 mg iron).
The only excipients are water for injection and sodium
hydroxide for pH adjustment (pH 10.9) [37,40].
IS should be only given intravenously; either as an i.v. drip
infusion (diluted in 0.9% sodium chloride solution), a slow
i.v. injection or directly into the venous line of a dialysis
machine. The total dose of IS should be individually deter-
mined based on the calculated total iron deficit [41]. Like other
iron carbohydrate complexes for parenteral use, IS is mainly
taken up via endocytosis by the macrophages of the
RES [22,26]. It is not suitable for intramuscular administra-
tion [42]. In the case of weaker iron carbohydrate complexes
such as IS and ferric gluconate, the carbohydrate is largely dis-
sociated in the plasma, and essentially only the polynuclear
iron core is taken up by the macrophages [26]. Iron that is
released in the blood can be directly taken up by transferrin
and other proteins (forming nontransferrin bound iron).
Accordingly, IS is given at lower single doses (in general
200 mg iron up to 3 times a week) than the more stable prod-
ucts such as ferric carboxymaltose (Table 1) [30]. In patients
with hemodialysis-dependent CKD (HD-CKD), the admin-
istration of lower doses at short intervals fits well to the usual
hemodialysis schemes.
4. Pharmacokinetics and pharmacodynamics
In healthy volunteers (n = 12, 50 -- 84 kg), IS (Venofer, single
dose, 100 mg iron) was quickly cleared from serum with a ter-
minal half-life of 5.3 ± 1.6 h and the total body clearance was
1.23 ± 0.22 l/h (20.5 ± 3.7 ml/min) [43]. Renal elimination of
iron contributed very little to the overall elimination (on
average < 5%). Serum ferritin levels increased significantly
after 8 -- 10 h and had doubled after 24 h.
In anemic patients (n = 6), single-dose administration of
100 mg iron with radiolabeled (52Fe/59Fe) IS complex was
followed by rapid uptake into the liver, spleen and bone mar-
row, reaching maximum rates at 10, 20 and 100 min after
administration, respectively [44]. Serum ferritin and transferrin
saturation (TSAT) increased within 24 h and 1 week. Up to
97% of the administered iron was utilized for red blood
cell (RBC) synthesis and both ferritin and TSAT returned
to baseline levels within 3 -- 4 weeks.
5. Efficacy
Notably, the IS complex was already developed in the 1940s






















































































































































































































































































































































































































































































































































































































































































































































































































































today. Therefore, many studies were conducted as investigator
initiated trials in different countries using a wide variety of
study designs and end points. This limits the comparability
and combined analyses of studies and therefore, published,
representative studies using Venofer in a variety of patient
populations were selected for inclusion in this review on
the basis of their patient numbers, study design, and assessed
efficacy and safety parameters.
The efficacy of IS in the treatment of ID has been proven in
patients with a wide range of underlying conditions that cause
or are associated with anemia (e.g., CKD, gastrointestinal
disorders, pregnancy/postpartum, CHF and cancer). Overall,
IS treatment improved iron status (ferritin, TSAT) and
increased Hb levels with or without ESA therapy. When
used in combination with ESA therapy, IS reduced ESA
dose requirements substantially.
5.1 Chronic kidney disease
A comparison of IS (100 mg iron/dose in hemodialysis
patients, 200 mg iron/dose in peritoneal dialysis patients) and
oral ferrous succinate in two separate prospective, randomized
studies with recombinant human erythropoietin (rHuEPO)-
treated patients on maintenance dialysis showed statistically sig-
nificantly better outcomes in Hb, hematocrit (Hct), serum fer-
ritin and TSAT in the IS groups during the entire study periods
(12 and 8 weeks, respectively; all p < 0.05) [45,46]. Furthermore,
rHuEPO dose requirements at the end of both studies
were significantly lower with IS compared to oral iron (-20.1
and -26.6%, respectively; p < 0.05). In HD-CKD patients
with documented hypersensitivity to iron dextran who received
erythropoietin twice weekly at a constant dose, a weekly dose of
IS (100 mg iron given over 5 -- 10 min for 8 weeks) signifi-
cantly increased mean Hct (23.8 -- 32.3%; p < 0.0001), serum
ferritin (185 -- 599 ng/ml; p < 0.0001) and serum iron
(29.3 -- 76.7 ng/ml; p < 0.01) [47].
The effectiveness of IS in anemic nondialysis CKD (ND-
CKD) patients without concomitant ESA treatment has
been shown in two single-arm studies. Compared to baseline,
IS, given as 200 mg iron dose either monthly for 1 year or
weekly for 4 weeks, significantly increased mean Hb, serum
ferritin and TSAT from the first post-baseline assessment at
month 3 onward or after the 4-week study period, respec-
tively [48,49]. In a randomized trial comparing IS (five
200 mg iron doses over 14 days) to oral ferrous sulfate
(65 mg iron thrice daily for 56 days) for the treatment of
anemic, stage 3 -- 5, ND-CKD patients, IS treatment resulted
in significantly more Hb responders (44.3 vs 28.0% with Hb
increase ‡ 1 g/dl; p = 0.0344), more patients achieving Hb
levels ‡ 11 g/dl (59.5 vs 43.2%; p = 0.0165) and a higher
mean Hb increase (0.7 vs 0.4 g/dl; p = 0.0298) [50].
5.2 Inflammatory bowel disease
One randomized, controlled, 20-week superiority study
compared IS (200 mg iron weekly or biweekly until cumu-
lative dose was reached) and oral ferrous sulfate for the
treatment of IDA in patients with inflammatory bowel dis-
ease [51]. The study showed significantly better outcomes in
the IS arm for two of three primary end points: less IS-
treated patients remained anemic (16 vs 41%; p = 0.007;
Hb < 12 g/dl [females] or < 13 g/dl [males]) and more
patients achieved Hb reference levels (42 vs 22%;
p = 0.04; Hb ‡ 13 g/dl or ‡ 15 g/dl [f/m]). The difference
in the percentage of Hb responders (Hb increase > 2 g/dl)
at week 20 was in favor of IS and close to significant
(66 vs 47%; p = 0.07). Notably, all patients in the IS group
achieved the recommended serum ferritin target (> 100 ng/
ml), whereas only 28% in the oral iron group achieved this
target. This might be partly due to the fact that all patients
tolerated IS, whereas 24% discontinued ferrous sulfate due
to intolerance.
Another study that investigated hematological response to
IS and oral ferrous sulfate allocated patients with inflamma-
tory bowel disease and Hb levels < 10 g/dl (mean baseline
Hb 8.8 g/dl) to IS (200 mg iron twice a week until calculated
iron deficit) and patients with Hb levels ‡ 10 g/dl (mean
baseline Hb 11.3 g/dl) to oral ferrous sulfate (106 mg iron
per day after the principal meal) [52]. Eighty-nine percent
of patients receiving oral iron for moderate anemia normal-
ized Hb levels. Despite their lower baseline Hb, also 77% of
IS-treated patients achieved normal Hb levels (Hb ‡ 12 g/dl
or ‡ 13 g/dl [f/m]) after 3 months. Furthermore, Hb levels
correlated with the quality of life score CCVEII-9 (a
9-item questionnaire including the most representative items
of the 36-item Inflammatory Bowel Disease Questionnaire;
p < 0.0001).
A randomized comparison of IS (200 mg iron twice
weekly up to 11 times until calculated iron deficit) and ferric
carboxymaltose (once-weekly infusions of 1000 or 500 mg
iron depending on baseline Hb and body weight)
showed similar response rates to IS as the studies above
(61.8% achieving normal Hb, 53.6% achieving Hb
increase ‡ 2 g/dl); yet response rates to ferric carboxymaltose
were significantly better (72.8 and 65.8%, respectively;
p < 0.015 and p = 0.004) [53].
5.3 Obstetrics and gynecology, women’s health
Among three studies that compared IS and oral iron in
pregnant women with IDA, two used ferrous sulfate
salt [54-56] and one iron polymaltose complex [57] as compar-
ator. In pregnant women with a gestational age < 32 weeks
and severe IDA (Hb < 9.0 g/dl, serum ferritin < 20 ng/ml),
treatment with IS (200 mg iron every 1 -- 3 days until cal-
culated iron deficit) resulted in significantly higher mean
Hb levels (12.9 vs 11.1 g/dl; p £ 0.001; baseline 7.6 g/dl
in both groups) than oral ferrous sulfate treatment (60 mg
iron thrice daily) [54]. IS-treated patients achieved maxi-
mum Hb levels in approximately half the time (6.9 vs
14.9 weeks; p £ 0.001) and also significantly higher serum
ferritin levels (96 vs 52 ng/ml; p £ 0.001; baseline 12 ng/ml
in both groups).
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In pregnant women with less severe IDA (Hb 8 -- 10 g/dl,
serum ferritin < 50 ng/ml), randomization to a 4-week treat-
ment with IS (6  200 mg iron) or a higher oral ferrous sul-
fate dose (240 mg iron daily) resulted in similar Hb levels
(11.0 vs 11.1 g/dl; baseline 9.6 and 9.7 g/dl, respectively) [55].
Iron prophylaxis in pregnant women with Hb ‡ 10.5 g/dl
(gestational week 15 -- 20) showed similar efficacy among
patients randomized to IS (2 -- 3 times 200 mg iron) or to
oral ferrous sulfate (80 mg iron daily) until delivery [56].
A comparison of IS (400 mg iron daily until calculated iron
deficit) and oral iron polymaltose complex (300 mg iron
daily) in pregnant women with severe ID (Hb 8 -- 10.5 g/dl,
serum ferritin < 13 ng/ml; gestational age 26 -- 34 weeks)
showed a significantly higher Hb increase in the IS group at
weeks 2 and 4 after treatment initiation and until delivery
(0.6, 1.2 and 2.1 g/dl vs 0.2, 0.6 and 1.5 g/dl, respectively;
p < 0.005 at all time points) [57]. At birth, the target Hb of
11 g/dl was reached by 95.6% IS- versus 62.2% oral iron-
treated patients (p < 0.001).
In a randomized study in postpartum women with IDA
(Hb < 9 g/dl, ferritin < 15 mg/l at 24 -- 48 h post-delivery),
treatment with IS (200 mg iron on days 2 and 4) resulted in
significantly higher Hb levels at days 5 and 14 (9.9 and
11.1 g/dl vs 7.5 and 9.0 g/dl, respectively; both p < 0.01)
than oral ferrous sulfate treatment (40 mg iron twice
daily) [58]. At day 40, oral iron-treated patients achieved sim-
ilar Hb levels as those in the IS group (11.2 vs 11.5 g/dl).
A randomized comparison of IS (100 mg iron daily for
3 days) and iron protein succinylate (40 mg iron daily for
1 month) in postpartum women with severe IDA
(Hb < 8 g/dl, serum ferritin < 10 ng/ml) showed significantly
higher Hb levels in IS-treated patients after 1 and 4 weeks
(8.8 and 12.6 g/dl vs 8.1 and 10.3 g/dl) [59]. However, in these
two trials, the daily oral iron dose was suboptimal.
Finally, a placebo-controlled study in fatigued, nonanemic
premenopausal women with low ferritin levels (Hb ‡ 12 g/dl,
serum ferritin £ 50 ng/ml) showed a trend for greater
improvement in fatigue (Brief Fatigue Inventory question-
naire) in patients treated with IS (4 times 200 mg iron over
2 weeks) that reached significance in those with serum
ferritin £ 15 ng/ml [60].
5.4 Oncology
Two prospective, randomized trials have been performed to
assess the efficacy of IS treatment in cancer patients receiving
ESAs. In anemic patients with lymphoproliferative malignan-
cies not receiving chemotherapy, addition of IS (100 mg iron
once weekly from weeks 0 -- 6 followed by 100 mg every sec-
ond week from weeks 8 to 14) to epoetin-b resulted in signif-
icantly faster and greater Hb increase (vs baseline) from week
8 onward when compared to no iron treatment (p < 0.05) [61].
Accordingly, end of study Hb levels were also higher in the IS
arm (difference in mean Hb 0.99 g/dl; p = 0.0023) and
a higher percentage of patients achieved a Hb
increase ‡ 2 g/dl (87 vs 53%; p = 0.0014). From week
5 onward, mean epoetin dose requirements were consistently
lower in the IS arm resulting in a 15% lower cumulative epoe-
tin dose over the study period (p = 0.059) and a 24% lower
epoetin dose at the end of the study. A subsequent cost anal-
ysis estimated that the lower epoetin dose requirements in the
IS arm translate into cost savings of e670 -- 747 over the
16-week study period, depending whether costs for loss of
leisure time are considered or not [62].
In multiple myeloma or lymphoma patients after autolo-
gous hematopoietic cell transplantation, supplementation of
darbepoetin-a with IS (200 mg iron on days 28, 42 and
56 post-transplant) increased the percentage of patients with
Hb increase ‡ 2 g/dl from 88 to 100% and reduced the
median time to response from 28 to 25 days (p = 0.0231)
compared to no iron supplementation [63]. The percentage
of patients requiring RBC transfusions and the cumulative
darbepoetin-alfa dose were significantly lower in the IS arm
(0 vs 11.1%; p = 0.0276 and 1210 vs 1440 µg; p = 0.015,
respectively). Overall cost savings for drug acquisition when
using IS supplementation were estimated to e444 per patient.
Otherwise, the use of IS without additional ESA treatment
could also benefit at least some patients in terms of improved
Hb levels and reduction of RBC transfusions as suggested by
early studies in patients with gynecological cancers who
received chemotherapy [64,65] and a prospective observational
study in patients with cancer- and chemotherapy-associated
anemia [66].
5.5 Preoperative iron treatment
In the context of perioperative PBM, that is, the prevention of
perioperative anemia and minimization of blood transfu-
sions [25], the Network for Advancement of Transfusion Alter-
natives recommends that nutritional deficiencies such as ID
are treated before ESAs are used for anemic patients [17]. Since
the underlying conditions in patients scheduled for elective
surgery are often associated with inflammation or blood loss
that exceeds absorption of oral iron, management of iron sta-
tus with i.v. iron should be considered in patients lacking a
response to oral iron. Despite the importance of this topic,
high-quality prospective studies that are sufficiently powered
are sparse.
A very small study in 12 patients with normal Hb and iron
status that were due for elective surgery showed no significant
difference in Hb increase of patients treated preoperatively
with rHuEPO and IS (200 mg iron twice weekly) or ferrous
sulfate (160 mg daily for 3 weeks) [67]. However, IS was asso-
ciated with significantly higher reticulocyte counts and pre-
vented iatrogenic iron depletion. In a similar trial, oral iron
was as effective as i.v. iron in supporting preoperative EPO-
driven stimulation of erythropoiesis, but transfusions were
not reported [68].
In anemic, iron-deficient patients (Hct < 34%, serum
iron < 700 µg/l) with gastrointestinal or colorectal cancer
scheduled for elective surgery, a combination of rHuEPO
and IS (200 mg iron on 12 consecutive days) allowed for
Iron sucrose




























































preoperative, autologous blood donations by 11/11 patients
compared to none among patients treated with IS alone [69].
Furthermore, the proportion of patients with perioperative
blood transfusions was reduced from 4/11 to none with the
combination treatment.
Patients with IDA (Hb < 9 g/dl) due to menorrhagia who
were scheduled for surgery 3 weeks later and received IS
(200 mg iron thrice per week until calculated iron deficit)
achieved significantly better postoperative Hb levels (10.5 vs
8.6 g/dl; p < 0.0001) than those treated with oral iron protein
succinylate (80 mg iron daily) [70]. However, the oral iron
dose used in this trial was suboptimal.
5.6 Perioperative iron treatment
A pooled analysis of observational data from 2547 patients
from a single institution who underwent major orthopedic
surgery compared postoperative outcomes of patients who
received very-short-term perioperative i.v. iron administration
(IS or ferric carboxymaltose with or without rHuEPO) or
standard treatment [71]. Intravenous iron was associated with
reduced rates of autologous RBC transfusions (32.4 vs
48.8%), postoperative nosocomial infection (10.7 vs 26.9%)
and 30-day mortality (4.8 vs 9.4%), and shorter length of
hospital stay (11.9 vs 13.4 days) (all p < 0.01) in hip fracture
patients. Transfusion rates and hospital stay were also reduced
in iron-treated arthroplasty patients (8.9 vs 30.2% [p < 0.01]
and 8.4 versus 10.7 days [p < 0.05], respectively). However,
the quality of evidence gathered from pooled observational
analyses is questionable.
Four randomized controlled trials have examined the
impact of perioperative i.v. iron. In a small double-blind trial,
including patients with post-operative Hb between 7.0 and
9.0 g/dl on day 1 after cardiac or orthopedic surgery,
38 patients were randomized between no treatment, i.v. IS
200 mg on days 1, 2 and 3, and the same schedule of i.v. IS
plus rHuEPO 600 U/kg on days 1 and 3 post-surgery [72].
Hb values on day 7 as well as 6 weeks after surgery were not
different in the three groups. In another double-blind trial,
120 anemic (Hb 7 -- 10 g/dl) patients after cardiac surgery
were randomized between no treatment, i.v. IS and IS plus
rHuEPO 300 U/kg once [73]. The i.v. IS dose was 200 mg
daily until reaching the total iron deficit as calculated by the
so-called Ganzoni formula: total iron deficit (mg) = 2.4 
body weight (kg) (target Hb [12 g/dl] - lowest Hb). Hb val-
ues, measured daily until day 5 and then on days 15 and 30,
were not different in the three groups and no significant dif-
ference in transfusion needs was observed among the three
groups (22, 25, and 17% of patients transfused in the no
treatment, i.v. iron alone and i.v. iron + rHuEPO group,
respectively). The largest randomized trial compared IS treat-
ment (3 times 200 mg iron at 48 h intervals starting at the day
of admission) and standard clinical management in
200 patients undergoing hip fracture repair surgery (no
patient received EPO) [74]. In the overall population, there
was no significant difference in transfusion requirements,
length of stay, morbidity and mortality between the two
groups. Only in subgroups of patients with surgery for intra-
capsular fractures or with preoperative Hb > 12 g/dl, post-hoc
analysis showed significant reductions in RBC transfusion
requirements in the IS arm (14 vs 46% [p < 0.005] and
19 vs 35% [p < 0.05], respectively). The last trial was a
double-blind study performed in 159 patients undergoing
cardiopulmonary bypass surgery [75]. Group 1 received i.v.
IS 3  100 mg/d pre- and postoperatively plus oral placebo,
group 2 i.v. placebo plus oral ferrous fumarate 105 mg/d peri-
operatively and for 1 month after discharge, and group 3 the
oral and i.v. placebos. No intergroup differences in Hb values
or in blood transfusion requirements were found during the
whole postoperative period.
In conclusion, four randomized controlled trials did not
demonstrate benefits of perioperative i.v. iron. However, these
trials included no more than 520 patients in total and one
study identified some subgroups of patients who may have
benefited. Therefore, before the use of perioperative i.v. iron
is abandoned, further studies involving large numbers of
patients should be performed to evaluate the efficacy and
safety of i.v. iron administration in surgical patients.
5.7 Chronic heart failure
A small study (n = 35) in iron-deficient patients with CHF
(serum ferritin < 100 ng/ml or serum ferritin 100 -- 300 ng/
ml and TSAT < 20%) showed significant improvements
(p < 0.05) of absolute peak oxygen consumption, New York
Heart Association (NYHA) functional class, TSAT and ferri-
tin among anemic patients (Hb < 12.5 g/dl) who received a
16-week treatment with IS (200 mg iron weekly until
ferritin > 500 ng/ml, followed by 200 mg iron monthly) com-
pared to no treatment [76]. Notably, even nonanemic patients
in the IS arm of this small study experienced a strong trend
toward improvement in NYHA class compared to controls
(p = 0.08). Changes in Hb levels were not significantly differ-
ent between the treatment arms.
5.8 Pediatric populations
Limited, nonrandomized, studies have been performed in
children. One retrospective study in pediatric non-CKD
patients aged 3 months to 18 years who were treated with IS
with individual doses of 25 -- 500 mg iron revealed significant
improvements in Hb levels compared to oral iron in children
who were refractory to oral iron or had malabsorption
(+3.1 vs +0.05 g/dl; p < 0.001 and +1.9 vs +0.4 g/dl;
p = 0.04, respectively) [77].
Two studies were performed in iron-deficient children and
adolescents with low Hb levels [78,79] and treated with IS at
individual doses of 6.5 -- 18.1 mg iron/kg and 5 mg/kg,
respectively. The study in 18- to 180-month-old children
who were scheduled for elective surgery showed significant
improvements in Hb from month 1 to the end of the
3-month study period [78]. Children in the control group
who were treated with oral ferrous glycine sulfate (no details
Y. Beguin & A. Jaspers




























































on dosing reported) achieved a similar Hb increase. The sec-
ond study in IS-treated children (age 11 months to 16 years)
who were unresponsive to oral iron, showed significant
improvements in Hb from 7.4 g/dl at baseline to 9.3 g/dl
on day 14 and 12.4 g/dl after 6 months [79].
6. Safety and tolerability
Since the clinical development of IS started already some
70 years ago, safety-related aspects in early trials were often
not reported in the same detail as for newer drugs. More
recent trials, when IS was already well-established, rather
focused on specific treatment regimens (e.g., combination
with ESAs) or patient populations (e.g., patients with prior
intolerance to other i.v. iron products). Among the 36 pub-
lished clinical studies [45-50,55-60,64,65,70,74,76-91] that are
included in the clinical dossier of Venofer, 26 reported at
least some details about adverse drug events; 3 of those
reported at least possibly related serious adverse events (all
nonfatal, Table 2) [51,76,77]. Three reports included only
general statements on safety without further details (e.g.,
no serious adverse reactions were noted) [47,48,64]. Five
reports mentioned that no drug-related adverse events or
no adverse events at all have been observed in IS-treated
patients [45,46,49,52,65]. Two reports did not provide any safety
information [84,88].
Overall, taste disturbance (dysgeusia) is the most common
adverse event related to IS that has been reported in 2 -- 24%
of patients among 12 of the above-mentioned studies
(Table 2). In general, dysgeusia is of transient and clinically
insignificant nature and hardly results in treatment discontin-
uation. Gastrointestinal adverse events were reported for
1 -- 13% of IS-treated patients in 13 of the published studies.
In studies that included oral iron as a comparator, gastroin-
testinal adverse events occurred generally at a lower rate in
the IS than in the oral iron arm (17 -- 40%). In practice, there
is a very low incidence of anaphylactoid or hypersensitivity
reactions with IS, and none were reported in the published
studies listed here (Table 2). In patients with HD-CKD and
documented hypersensitivity to iron dextran, a weekly dose
of IS (100 mg iron) was well tolerated without reoccurrence
of hypersensitivity reactions during the 8-week study
period [47]. Hypotension and rash/pruritus were reported in
four publications each, flushes or dizziness in two studies
each (Table 2).
In pediatric non-CKD patients (3 months to 18 years)
who received 510 IS administrations (25 -- 500 mg iron),
individual IS doses < 3 mg iron/kg body weight were well tol-
erated without drug-related adverse events [77]. Five mild
events were observed with individual doses of 3.0 -- 5.1 mg
iron/kg, and only one serious-related adverse event (body
aches, facial swelling, thready pulse and hypotension) was
reported after an individual 500 mg iron dose that was given
within 35 min (i.e., 200 mg above the recommended dose
corresponding to an individual dose of 8.8 mg/kg).
Apart from clinical trial data, three analyses of the US FDA
and WHO pharmacovigilance databases covering periods
from 1997 to 2009 evaluated adverse event reports of IS,
iron dextranes and ferric gluconate [32,92,93]. Across all analy-
ses, the reported adverse event rates appeared to be lowest
with IS; particularly when compared to dextran-containing
preparations. The most recent analysis of data from 16 Euro-
pean countries, the United States and Canada (Jan 2003 -- Jun
2009) showed a significantly lower risk for all adverse events
(odds ratio, 0.13; p < 0.0001) or serious allergic adverse events
(odds ratio, 0.07; p < 0.0001) for IS compared to iron
dextran [93]. Also compared to sodium ferric gluconate, IS
had a significantly lower risk for all adverse events (odds ratio,
0.63; p < 0.0001) or serious allergic adverse events (odds ratio,
0.31; p = 0.001).
In 2013, the European Medicines Agency (EMA) pub-
lished an assessment report [94] that reviewed the risk of aller-
gic reactions of all i.v. iron products registered in the
European Union and concluded that the benefits of i.v.
iron-containing medicinal products continue to outweigh
the risks in the treatment of ID situations when the oral route
is insufficient (e.g., due to increased hepcidin activity and
other inhibitors of cellular iron homeostasis [26]) or poorly tol-
erated. Notably, no test dose should be applied anymore;
however, staff trained to evaluate and manage anaphylactic
or anaphylactoid reactions as well as resuscitation facilities
should be immediately available.
Since iron can modulate the activity of the immune system
and iron sequestration by monocytes and macrophages has
been suggested as a mechanism to withhold iron from patho-
gens or infected cells [10], a frequently raised question is
whether i.v. iron increases the risk of infections. However, rel-
evant clinical evidence is sparse and inconclusive [81,95,96].
A large multicenter safety study that evaluated an iron status
correction and a maintenance IS dosing regimen in 665
hemodialysis patients (covering 8583 doses of 100 mg iron)
reported lower rates of infection-related hospitalizations
(relative risk 0.54, p < 0.001) and mortality (relative risk
0.61, p = 0.08) compared with a historical general hemodial-
ysis population [81]. Conversely, a US cohort study
(117,050 HD patients) suggested a higher risk of infection-
related hospitalizations with high versus low iron dose (hazard
ratio [HR] 1.05 [1.02 -- 1.07]) and bolus versus maintenance
dose (HR 1.05 [1.05 -- 1.11]) [97]. However, the study does
not provide any information about the distribution of admin-
istered iron compounds. A review of 75 studies (42 of them
investigated IS) included a meta-analysis of 24 studies
(n = 4400 patients) that suggests an association between i.v.
iron and an increased risk of infection (risk ratio 1.33; 95%
confidence interval 1.10 -- 1.64) [95]. However, the authors
of this analysis mentioned themselves that their finding might
also be a false positive result since infection is generally not a
predefined end point and missing data could have created a
bias in the analysis. A study investigating an ‘aggressive’ IS
treatment (100 mg iron doses until a TSAT > 30% and serum
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ferritin up to 1200 ng/ml) showed no increase in the inci-
dence of culture positive bacteremias, pneumonias, soft tissue
infections or osteomyelitis over a 1-year period [96].
7. Regulatory affairs and experience with IS
follow-on compounds
Iron(III)-hydroxide sucrose complex has received the first
marketing authorization in December 1949 in Switzerland,
where the product was first launched in 1950 (formerly mar-
keted as Ferrum Hausmann, now Venofer). Until August
2013, Venofer had received marketing authorization in a
total of 85 countries worldwide and is marketed in all
of them.
A generic follow-on product is considered therapeutically
equivalent (and thus eligible for substitution) if it comprises
the same active pharmaceutical ingredient and dosage form
as well as comparable pharmacokinetic properties demon-
strated in a cross-over healthy volunteer study [98]. However,
the synthetic IS complex (and iron carbohydrate complexes
in general) comprises a macromolecular and nanoparticulate
structure that may even exceed the complexity of some biolog-
icals [38,99]. Accordingly, IS is no single substance that can be
isolated or fully characterized, and the physicochemical and
biological properties of IS preparations (e.g., structure of the
iron core, complex stability, biodisposition and bioavailability
of iron after infusion) can be affected by subtle differences in
the multistep manufacturing process. Therefore, IS might be
considered as a nonbiological complex drug (NBCD) [38].
While the originator IS received regulatory approval based
on clinically assessed efficacy and safety, regulatory assessment
of follow-on products is subject to a lively discussion since the
abridged pathway for small-molecule generics does not seem
appropriate for follow-on products of a NBCD and the biosi-
milar pathway cannot be applied to nonbiologicals [39,99].
The EMA highlighted regulatory issues with the assessment
of nanoparticle iron follow-on products in a first reflection
paper on nonclinical requirements in 2011 and a draft reflec-
tion paper on nonclinical and clinical data requirements that
has been open for consultation until 28 February 2014 [100].
Also, the US FDA issued a draft guidance on the evaluation
of IS follow-on products that recommends conduct of two
bioequivalence studies; one study assessing serum iron and
serum transferrin-bound iron in healthy subjects after admin-
istration of a 100 mg iron dose, and one assessing ‘sameness’
in physicochemical properties such as ‘labile iron determina-
tion under physiologically relevant conditions’ [101].
Accordingly, experts from academia, industry and regula-
tory bodies suggest a stepwise similarity approach that
includes appropriate clinical and/or nonclinical studies that
evaluate pharmacokinetics, pharmacodynamics and safety/
efficacy of a nonbiological complex drug’s follow-on prod-
ucts in relevant patient populations [38,99,102,103]. As long as
proof of therapeutic equivalence and similar safety profiles
by appropriate studies is missing, interchange and automatic
substitution between nonbiological complex drugs and their
follow-on products should be discouraged [39].
Few studies have touched on this topic. A retrospective
study of 658 female patients who received the IS originator
or a follow-on product in two different dilutions (ISSd1,
ISSd2) showed significantly fewer adverse drug reactions
with the originator (IS: 1.8%, ISSd1: 11.0%, ISSd2: 14.3%;
p < 0.02) [33]. The most commonly observed adverse events
were injection site reaction (IS: 1.8%, ISSd1: 6.2%, ISSd2
8.2%; p < 0.05) and phlebitis (IS: 0%, ISSd1: 4.8%, ISSd2
4.7%; p < 0.05). An observational study in 75 consecutive,
stable patients with HD-CKD in a French hemodialysis cen-
ter investigated Hb and iron status parameters during two
27-week periods before and after a switch from the IS origina-
tor to a follow-on product [35]. The study showed significantly
lower mean Hb levels (11.4 ± 1.1 g/dl vs 11.8 ± 1.0 g/dl;
p = 0.005), as well as ferritin and TSAT after the switch. Con-
versely, the mean ESA dose requirements per patient to main-
tain or re-achieve target Hb levels increased by 13.8% (from
0.58 ± 0.52 to 0.66 ± 0.65 µg/kg/week; p = 0.13).
8. Cost-effectiveness
Intravenous iron supplementation can result in substantial
ESA dose reductions and corresponding net cost savings to
health-care providers [62,104,105]. Furthermore, reducing RBC
transfusions needs [65,106] can potentially reduce costs for
providing RBC units, hospitalization and management
of complications.
Very few studies compared drug costs between i.v. iron
preparations [107,108]. Two studies evaluated the effects of IS
and ferric gluconate in hemodialysis patients in a switch
(n = 100) and a parallel group study (n = 59), respectively.
The first study reported a reduction of iron dosage from
264 to 153 mg iron/month after 9 months of IS treatment
and a trend for reduced ESA dosage [108]. The second study,
a randomized, controlled comparison (IS: 250 mg iron
monthly vs ferric gluconate: 62.5 mg iron weekly), showed
no significant difference in ESA dose requirements [107].
Switching from the IS originator to an IS follow-on prod-
uct in a French hemodialysis center nonsignificantly increased
the cumulative anemia drug (ESA + iron) expenditure by
11.9% [35].
9. Conclusion
Clinical experience demonstrates that treatment with i.v. IS
corrects both absolute ID (i.e., depleted iron stores) as well
as FID (insufficient availability of iron to the bone marrow
despite adequate iron stores) and promotes erythropoiesis. IS
is effective and well-tolerated in patients who are in clinical
need for rapid iron supply, cannot tolerate oral iron therapy
or are noncompliant or where oral iron preparations are inef-
fective. The efficacy and tolerability of IS in the treatment
of IDA have been demonstrated in patients with a wide range
Y. Beguin & A. Jaspers




























































of underlying conditions that cause or are associated with ane-
mia, including CKD, gastrointestinal disorders, pregnancy,
postpartum, CHF and cancer. In the preoperative or periop-
erative setting, additional data are warranted.
10. Expert opinion
IS is the most frequently used i.v. iron compound for the
treatment of ID and IDA in a broad range of therapeutic
areas; particularly in patients with impaired iron absorption
(e.g., due to chronic inflammatory conditions) or rapidly
increased iron consumption after treatment with ESAs. IS,
like available i.v. iron preparations in general, can overcome
both the low intestinal absorption of orally ingested iron as
well as the reduced release of iron from iron storing cells of
the RES.
In contrast to the common misconception that i.v. iron
would be trapped in the RES of patients with inflammatory
conditions, the release of iron from iron stores is only reduced
and not completely blocked. Since iron is still released,
though at a lower equilibrium rate, there is no risk of chronic
iron overload as long as i.v. iron is administered to individuals
with confirmed ID (i.e., serum ferritin < 100 ng/ml or
TSAT < 20%).
IS treatment is associated with increases in Hb concentra-
tions with or without ESA therapy and improvements in
iron status increasing both TSAT and ferritin. In studies com-
paring i.v. IS with an oral iron preparation, achievement of
hematological response was generally faster (if early time
points were recorded) or more frequent. In the long-term
and absence of chronic inflammatory conditions, daily treat-
ment with oral iron may compensate the early advantages of
i.v IS provided that patients tolerate oral iron and stay compli-
ant with the treatment. Furthermore, the use of IS in addition
to an ESA-based anemia therapy can substantially reduce ESA
dose requirements and thus improve cost-effectiveness since
the costs of ESAs are still major drivers of total anemia
treatment costs.
In general, i.v. iron should be considered for patients with
FID and impaired iron absorption due to chronic inflamma-
tory conditions and for patients with absolute ID or IDA
requiring rapid resolution of ID or anemia. A trial of oral
iron should be considered in patients with absolute ID and
normal iron absorption if resolution of ID is not time critical.
IS has an extensive safety and tolerability record in a
wide range of patients with ID. The most commonly
reported adverse event in clinical trials was dysgeusia (taste
disturbance), which rarely led to discontinuation of ther-
apy. The incidence of serious drug-related adverse events
with IS is low. Three analyses of surveillance data covering
the period from 1997 to 2009 confirmed the good tolera-
bility of IS compared to other iron products, particularly
iron dextran. In addition, IS has been shown to be well
tolerated by patients with documented prior intolerance
of iron dextran and/or iron gluconate. No patient with
intolerance to iron dextran or iron gluconate had an
anaphylactic reaction to IS.
The extensive safety and tolerability record of IS, including
a low frequency of hypersensitivity reactions, supports the
recent recommendation of the EMA that no test dose needs
to be applied prior IS administration provided that trained
staff and equipment for the evaluation and management of
potential anaphylactic or anaphylactoid reactions and resusci-
tation are available. Overall, there is no confirmed association
between i.v. IS when used according to the label and the rate
of infections, but this remains to be further investigated pro-
spectively. In patients with active infection, however, the use
of i.v. iron should be generally avoided.
First reports about the clinical experience with follow-on
products of the IS originator raise questions whether these
products are all therapeutically equivalent and should qualify
for automatic substitution without clinical proof of equiva-
lence in the intended patient population.
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